Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017
Bone Therapeutics to focus in future on the development of its MSC cell and gene therapy pipeline Gosselies, Belgium, 27 July…
Pharmaceuticals, Biotechnology and Life Sciences
Bone Therapeutics to focus in future on the development of its MSC cell and gene therapy pipeline Gosselies, Belgium, 27 July…
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, July 27, 2021 (GLOBE…
MONTREAL, July 27, 2021 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research,…
Pompano Beach, Fl., July 27, 2021 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a…
– Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine, in patients with advanced solid…
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ETSOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) —…
NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel…
HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for…
REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second…
— ‘Coming Soon’ placeholders for all three SKUs of VAZALORE to be positioned prominently on shelves — VAZALORE PLx Pharma…